Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing treatments for two major neurological conditions affecting hundreds of millions worldwide: multiple sclerosis (MS) and the acute effects of alcohol intoxication. The company's pipeline includes Lucid-MS, a patented new chemical entity for MS, and unbuzzd, a proprietary dietary supplement for alcohol metabolism.
Multiple sclerosis is one of the most common neurological diseases in young adults, with an estimated 2.9 million people living with MS globally, including about one million in the United States. The disease is typically diagnosed between ages 20 and 50, with a mean age of 32, and affects women at roughly twice the rate of men. Existing therapies often fall short, leaving a significant unmet need.
Lucid-MS takes a fundamentally different approach from current MS treatments, though the press release does not detail the mechanism. Supporting its phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital, which could provide critical data on the drug's effects.
Meanwhile, Quantum BioPharma developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This addresses a widespread issue, as alcohol consumption is common globally.
The company's focus on neurological disorders highlights the importance of innovation in areas where treatments are limited. If successful, Lucid-MS could offer new hope for MS patients, while unbuzzd may provide a practical solution for alcohol-related cognitive and physiological effects.
Investors should note forward-looking statements in the release, which involve risks and uncertainties that could cause actual results to differ materially. These include factors detailed in the company's SEC filings, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The company undertakes no duty to update this information unless required by law.
For more details, see the full terms of use and disclaimers on the InvestorBrandNetwork website. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
